Property of cytochrome P450 1A inducibility by polychlorinated/brominated biphenyls (Co-PXBs) detected in Japanese breast milk  by Kakutani, Hideki et al.
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Coplanar  polychlorinated/brominated  biphenyls  (Co-PXBs)  belong  to  a class  of struc-
turally  similar  chemicals  known  as  polyhalogenated  aromatic  hydrocarbons.  We  found  that
the  milk  of  Japanese  primiparous  and  multiparous  mothers  was  similarly  contaminated
with  Co-PXB  congeners.  Co-PXBs  time-  and  dose-dependently  increased  ethoxyresoruﬁn-
O-deethoxylase  (EROD  activity)  in HepG2  cells.  The  EROD  activity  of liver  microsomes
collected  from  C57BL/6  mice  exposed  to  these  congeners  substituted  with  one  or  two,  and
with  three  or  ﬁve  bromine  atoms  time-dependently  decreased  and  increased,  respectively.oplanar polychlorinated/brominated
iphenyls
reast milk contamination
-Ethoxyresoruﬁn-O-deethoxylase activity
These  results  indicate  that  introducing  bromine  into  the chemical  frame  of  a polychlori-
nated  biphenyl  tends  to increase  CYP1A  activity  in  vitro  and in  vivo  and  that  the  number
substituted  bromine  atoms  alters  the  metabolism  proﬁles.  If Co-PXBs  are  more  toxic  than
Co-PCBs,  our  ﬁndings  suggest  that  the  TEQ  of  Co-PXBs  is  important  for human  health  risk.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. IntroductionThe speciﬁc, highly hazardous xenobiotics known as
dioxins” comprising dibenzo-p-dioxins, dibenzofurans
Abbreviations: AhR, aryl hydrocarbon receptor; BFRs, bromi-
ated ﬂame retardants; Co-PBB, coplanar polybrominated biphenyl;
o-PCB, coplanar polychlorinated biphenyl; Co-PXB, coplanar poly-
hlorinated/brominated biphenyl; CYP, cytochrome P450; EROD,
thoxyresoruﬁn-O-deethoxylase; LDH, lactate dehydrogenase; MSW,
unicipal solid waste; PAHs, polycyclic aromatic hydrocarbons;
CDDs/DFs, polychlorinated dibenzo-p-dioxins and dibenzofurans;
XDDs/DFs, polychlorinated/brominated dibenzo-p-dioxins and dibenzo-
urans; REP, relative potency; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin;
EF, toxic equivalency factor; TEQ, toxic equivalent.
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and biphenyls are environmental and food contaminants.
These coplanar compounds are long-lived and ubiquitous
in the environment; and are detectable at picomolar levels
in foods and human tissues.
Similar to polychlorinated dibenzo-p-dioxins and
dibenzofurans (PCDDs/DFs), polybrominated and poly-
chlorinated/brominated dioxins, such as polybrominated
dibenzo-p-dioxins and dibenzofurans (PBDDs/DFs) and
polychlorinated/brominated dibenzo-p-dioxins and diben-
zofurans (PXDDs/DFs), are generated as by-products of
plastic materials containing precursors such as brominated
ﬂame retardants (BFRs) during combustion in munici-
pal solid waste (MSW)  incinerators [1,2]. Several studies
have identiﬁed PBDDs/DFs and PXDDs/DFs derived from
BFRs in ﬂy ash and/or ﬂue gas in various incinerators
[3,4]. To generate PXDDs/DFs from a mixture of bromine
and chlorine is easier than to generate PBDDs/DFs de
novo from all available bromine inside incinerators [5,6].
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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Coplanar polychlorinated (Co-PCBs) and coplanar poly-
brominated (Co-PBBs) biphenyls have been investigated in
detail [7–9], but little is known about coplanar polychlori-
nated/brominated biphenyls (Co-PXBs). These compounds
belong to a class of structurally similar chemicals known
as polyhalogenated aromatic hydrocarbons that includes
human endocrine disruptors such as Co-PCBs and they can
be formed by de novo synthesis from precursor BFRs. We
estimated that the generations of Co-PXBs and PXDDs/DFs
in municipal waste incinerators are similar, and that Co-
PXBs are easier to form from a mixture of bromine and
chlorine than Co-PBBs from all bromine available in an
incinerator. Because information about contamination lev-
els and the toxic potency of Co-PXBs is scant, further
investigation is required [10–12].
Cytochrome P450 1A (CYP1A) enzymes comprise a key
factor for human health as they can detoxify xenobiotics
such as pesticides and other environmental contaminants.
The ethoxyresoruﬁn-O-deethoxylase (EROD) activity of
CYP1A isozymes is widely used to measure CYP induc-
tion by dioxin-like compounds [13]. Increased EROD
activity is an established parameter for determining the
potency of aryl hydrocarbon receptor (AhR) agonists such
as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) [14]. The
relative effect potency (REP) of individual dioxins and
their related compounds is used to determine toxic and
biological effects relative to those of a reference com-
pound, usually TCDD. The total toxic equivalent (TEQ) is
operationally deﬁned as the sum of the products of the
concentration of each compound multiplied by its toxic
equivalency factor (TEF), and it can be estimated as the
total TCDD-like activity of a congener mixture [15]. In
the absence of robust data about Co-PXB toxicity, TEFs
have not been determined, but the TEF/REP values of
Co-PXBs are essential to estimate the toxicity of these
compounds.
Here, we investigated the amount of Co-PXB contam-
ination in Japanese breast milk and CYP1A inducibility in
HepG2 cells and in C57BL/6 mice exposed to Co-PXBs.
2. Material and methods
2.1. Dioxin standards
13C12-labelled and unlabeled PCDDs/DFs, Co-PCBs,
PXDDs/DFs and Co-PXBs used in this study were purchased
from Cambridge Isotope Laboratories (Tewksbury, MA,
USA). The congeners comprised seven PCDDs, 10 PCDFs
and 14 Co-PCBs with TEFs assigned by the WHO  in 2006, as
well as three PXDDs and ﬁve PXDFs as described [16]. The
eight Co-PXBs were 3,3′,4,4′,5-pentachlorobiphenyl (PCB
#126; PCB), 4′-monobromo-3,3′,4,5-tetrachlorobiphenyl
(structurally similar to PCB #126; #126-Br), 4′-
monobromo-2,3,3′,4-tetrachlorobiphenyl (structurally
similar to PCB #105; #105-Br), 4′-monobromo-2,3′,4,5-
tetrachlorobiphenyl (structurally similar to PCB #118;
#118-Br), 4′-monobromo-3,3′,4,5,5′-pentachlorobiphenyl
(structurally similar to PCB #169; #169-Br), 3,4-dibromo-
3′,4′,5′-trichlorobiphenyl (structurally similar to PCB
#126; #126-2Br), 3′4′5′-tribromo-3,4-dichlorobiphenyl
(structurally similar to PCB #126; #126-3Br) andports 2 (2015) 685–691
3,3′,4,4′,5′-pentabromobiphenyl (structurally similar
to PCB #126; PBB). Six congeners (PCB, #126-Br, #126-3Br,
#105-Br, #118-Br and #169-Br) and ﬁve congeners (PCB,
#126-Br, #126-2Br, #126-3Br and PBB) were used for the
determination of contamination levels in breast milk and
assays in vitro and in vivo, respectively.
2.2. Analysis of Co-PXBs in human breast milk
Our Institutional Review Board approved the study and
four primiparous (age, 25–28 y) and six multiparous (age,
22–37 y) women  provided written, informed consent to
donate breast milk at 5 and 30 days after delivery of
their newborns between 2010 and 2011 in Osaka Pre-
fecture, Japan. Samples (50 mL)  of breast milk collected
three times on the same day and shortly after eating were
stored at −40 ◦C. We  used isotope dilution to analyze the
amounts of PCDDs/DFs, PXDDs/DFs, Co-PCBs and Co-PXBs
in breast milk samples as described previous our reports
[11,12,16].
2.3. Methods for QA/QC and toxic evaluation of dioxin
congeners
We  compared the retention times and mass spec-
tra of duplicate samples containing PCDDs/DFs, Co-PCBs,
PXDDs/DFs and Co-PXBs with those of authentic standards.
Peak area ratios for (M)+/(M+2)+ were determined on SIM
chromatograms. Acceptance criteria were established from
rates of −30% to 30% determined from authentic standards.
The concentrations of pairs of congeners were corrected
by comparisons with the recovery of their respective 13C-
internal standards. Data were collected from samples with
recovery rates ranging from 60% to 120% of their respective
internal standards. Assuming that the toxicity of PXDD/DF
and Co-PXB congeners was equal to that of the corre-
sponding PCDDs/DFs and Co-PCBs [15], we  calculated the
contribution ratios of PCDDs/DFs, PXDFs/DFs, Co-PCBs and
Co-PXBs to the total TEQ using 2,3,7,8-tetrachlorobibenzo-
p-dioxin (TCDD) equivalency factors (WHO-2006 TEF).
Infant’s daily intake was calculated based on the average
infant’s consumption and the average infant’s body weight
to be 600 mL/day and 4 kg, respectively, from mother’s
questionnaire using average TEQ concentration.
2.4. Cell culture
The human hepatocarcinoma cell line HepG2 (American
Type Culture Collection, Rockville, MD,  USA) was  cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) contain-
ing 10% fetal bovine serum (FBS) at 37 ◦C and used between
passage numbers 25 and 30. We dissolved Co-PXB con-
geners in dimethyl sulfoxide (DMSO; ﬁnal concentration in
culture medium, 0.2% v/v) for assays in vitro. The cytotox-
icity of the Co-PXB congeners and DMSO was  determinedTesque, Kyoto, Japan) and CytoTox96 NonRadioactive Cyto-
toxicity assays (Promega, Madison, WI,  USA) of lactate
dehydrogenase (LDH) according to the respective manu-
facturer’s protocols.
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.5. Assays of EROD activity in vitro
HepG2 cells were seeded at a density of 3 × 104/well
f 96-well microplates and incubated for 1 h at 37 ◦C
ith culture medium containing 5 M 7-ethoxyresoruﬁn
Sigma–Aldrich, St. Louis, MO,  USA). Resoruﬁn-associated
uorescence was measured at 550 nm excitation and
95 nm emission using a SpectraFluor microplate reader
TECAN, Männedorf, Switzerland). The EROD activity was
ormalized to cellular protein contents determined using
CA protein assay kits (Thermo Scientiﬁc, Rockford, IL,
SA).
The dose–responses for EROD activity were modeled
sing the variable slope, sigmoid, Hill equation. The EROD
C50 is the concentration at which the induced enzyme
ctivity was halfway between the bottom and top of
ach dose–response curve calculated using Prism software
Graph Pad Software). The relative effect potencies (REPs)
f Co-PXBs were calculated based on EC50 values deter-
ined from EROD assays when the EC50 of TCDD was 1.0.
.6. Assay of EROD activity in vivo
Female C57BL/6 mice (SLC Inc., Shizuoka, Japan) were
oused at 23 ± 1.5 ◦C with a 12-h light/dark cycle and free
ccess to standard rodent chow and water. The mice were
llowed to adapt to their environment for at least 1 week
nd then experiments proceeded when they reached the
ge of 6 weeks according to the guidelines of Setsunan
niversity.
Liver microsomes were prepared as described in ref.
17]. Brieﬂy, the mice were given a single dose of 5, 10
nd 50 nmol/kg of Co-PXBs dissolved in saline containing
% ethanol and 10% Tween20 by oral gavage and then sacri-
ced with chloral hydrate 1, 2 or 3 days later. Excised livers
ere homogenized in 100 mM Tris–acetate buffer (pH 7.4),
eparated by centrifugation at 9,000 × g for 15 min  at 4 ◦C,
hen the supernatant was separated by centrifugation at
05,000 × g for 60 min  at 4 ◦C. The resulting pellet was
omogenized in 100 mM potassium pyrophosphate buffer
pH 7.4) and separated by centrifugation at 105,000 × g
or 60 min  at 4 ◦C. The microsomal pellet was ﬁnally
able 1
evels of PCDDs/DFs, PXDDs/DFs, Co-PCBs and Co-PXBs contamination in breast m
Dioxin analog Actual concentration (pg/g lipid) TEQ c
Range Median Average Range
Primiparous donors∑
PCDDs/DFs 42–172 42 84 2.4–∑
PXDDs/DFs 0–22 0 8.8 0–∑
Co-PCBs 12,866–54,863 12,866 30,539 1.1–∑
Co-PXBs 12–33 12 22 0.46–
Multiparous donors∑
PCDDs/DFs 26–179 81 92 0.42–∑
PXDDs/DFs 0–11 0 2.9 0–∑
Co-PCBs 2138–48,999 10,882 16,516 0.29–∑
Co-PXBs 9.5–54 22 27 0.42–
ange represents minimum to maximum concentration of dioxin analogs. Data 
ultiparous (n = 6) donors.ports 2 (2015) 685–691 687
resuspended in 10 mM Tris–acetate buffer (pH 7.4) and
stored at −80 ◦C. The protein concentration in the micro-
somes was determined according to the Lowry method
using bovine serum albumin as the standard.
Diluted liver microsomes were incubated with the
reaction mixture (50 mM phosphate buffer, 5 mM  MgCl2,
0.5 mM NADP+, 1 IU/mL G-6-P dehydrogenase and 2.4 M
7-ethoxyresoruﬁn) for 5 min  at 37 ◦C, then the reaction
started by adding 5 mM glucose-6-phosphate proceeded
for 10 min  at 37 ◦C. Resoruﬁn production was measured
using SPECTRA FLUOR.
2.7. Statistical analysis
The statistical signiﬁcance of differences in means was
determined using Student’s t-test or a one-way analysis
of variance (ANOVA) followed by Dunnett’s multiple com-
parison test. P values < 0.05 were considered signiﬁcant. All
data were statistically analyzed using Prism software.
3. Results
3.1. Contamination of breast milk with
∑
PCDDs/DFs,∑
PXDDs/DFs,
∑
Co-PCBs and
∑
Co-PXBs
We  determined the contamination levels of the
congeners,
∑
PCDDs/DFs (n = 17),
∑
PXDDs/DFs (n = 8),∑
Co-PCBs (n = 14) and
∑
Co-PXBs (n = 5) in mother’s milk.
The baseline characteristics of the 10 donors of breast
milk did not signiﬁcantly differ. The average lipid con-
tent of the milk was  3.6% (range, 2.3–4.6%). Tables 1 and 2
show the actual and TEQ concentrations of
∑
PCDDs/DFs,∑
PXDDs/DFs,
∑
Co-PCBs and
∑
Co-PXBs at 5 and 30 days
after neonatal delivery, respectively. Fig. 1A summarizes
the contribution ratio to the total TEQ concentrations of
the dioxin analogs, PCDDs/DFs, PXDDs/DFs, Co-PCBs and
Co-PXBs. The major components were PCDDs/DFs, Co-PCBs
and Co-PXBs, whereas the amount of PXDDs/DFs was neg-
ligible. This contribution of Co-PXBs cannot be ignored
because they account for 10% of the total TEQ concentra-
tion and yet only ﬁve congeners were selected for analysis.
The ratios of
∑
PCDDs/DFs,
∑
PXDDs/DFs,
∑
Co-PCBs and
ilk at 5 days after neonatal delivery in Japan.
oncentration (pg-TEQ/g lipid) Daily intake
(pg-TEQ/kg b.w./day)
 Median Average
12 5.1 6.3 28.4
0.012 0.0000085 0.003 0.014
7.7 3.8 4.1 18.5
1.1 0.78 0.8 3.6
4.6 1.4 1.9 8.6
0.005 0 0.001 0.005
7.2 2.9 3.0 13.5
1.4 0.73 0.81 3.6
are shown as means of duplicate samples from primiparous (n = 4) and
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Table  2
Levels of PCDDs/DFs, PXDDs/DFs, Co-PCBs and Co-PXBs contamination of breast milk at 30 days after neonatal delivery in Japan.
Dioxin analog Actual concentration (pg/g lipid) TEQ concentration (pg-TEQ/g lipid) Daily intake
(pg-TEQ/kg b.w./day)
Range Median Average Range Median Average
Primiparous donors∑
PCDDs/DFs 38–161 144 114 1.9–11 3.0 5.4 24.3∑
PXDDs/DFs 0–8.9 4.8 4.6 0–0.002 0 0.001 0.005∑
Co-PCBs 14,261–59,860 29,218 34,446 1.8–7.1 4.3 4.4 19.8∑
Co-PXBs 19–35 25 26 0.51–0.84 0.76 0.70 3.2
Multiparous donors∑
PCDDs/DFs 21–205 57 85 0.36–4.2 1.8 1.7 7.7∑
PXDDs/DFs 0–4.4 0.2 1.2 0–0.004 0.001 0.002 0.009∑
Co-PCBs 2749–15,441 11,418 10,257 0.56–3.2 1.1 1.9 8.6∑
Co-PXBs 13–28 21 21 0.45–1.2 0.68 0.75 3.4
s. DataRange represents minimum to maximum concentration of dioxin analog
multiparous (n = 6) donors.
∑
Co-PXBs to the total TEQ concentration did not signiﬁ-
cantly differ between primiparous and multiparous donors
at 5 and 30 days after neonatal delivery.
We  then compared the actual and TEQ concentrations
of each Co-PXB congener in more detail. Tables 3 and 4
show the actual and TEQ concentrations of #105-Br,
Table 3
Levels of contamination with Co-PXB congeners in breast milk at 5 days after neo
Co-PXB congener Actual concentration (pg/g lipid) TEQ co
Range Median Average Range
Primiparous donors
#105-Br 2.3–7.9 4.4 4.8 0.000
#118-Br 0–5.2 2.0 2.3 
#126-Br 1.3–4.8 2.6 2.8 0.
#126-3Br 1.1–4.1 1.4 2.0 0.
#169-Br 5.8–18 8.6 10 0.
Multiparous donors
#105-Br 0–7.6 5 7.2 0.000
#118-Br 2–18 2.9 3.4 
#126-Br 0.8–5.6 2.2 2.5 0.
#126-3Br 0.91–3.9 2.2 2.0 0.0
#169-Br 4.5–21 13 12 0.
Range represents minimum to maximum concentration of Co-PXB congeners. Da
multiparous (n = 6) donors.
Table 4
Levels of contamination with Co-PXB congeners in breast milk at 30 days after ne
Co-PXB congener Actual concentration (pg/g lipid) TEQ c
Range Median Average Range
Primiparous donors
#105-Br 2.1–12 3.1 5.7 0.000
#118-Br 6.4–8.5 7.9 7.6 0.00
#126-Br 2.1–3.7 2.8 2.9 0
#126-3Br 0.47–2.7 1.8 1.7 0.0
#169-Br 6.1–9.6 9.3 8.3 0
Multiparous donors
#105-Br 2.3–7.2 3.4 4.1 0.000
#118-Br 1.9–5.9 3.4 3.6 0.000
#126-Br 1.4–6.6 3.4 3.7 0
#126-3Br 0.41–2.4 1.1 1.3 0.0
#169-Br 3.3–13 8.6 8.4 
Range represents minimum to maximum concentration of Co-PXB congeners. Da
multiparous (n = 6) donors. are shown as means of duplicate samples from primiparous (n = 4) and
#118-Br, #126-Br, #126-3Br and #169-Br at 5 and 30
days after delivery, respectively. Fig. 1B and C summarizes
the contribution of Co-PXB congeners to the total actual
and total TEQ concentrations. The actual concentrations of
#105-Br and #169-Br were high in all milk samples and
those of #118-Br, #126-Br and #126-3Br were similar. On
natal delivery in Japan.
ncentration (pg-TEQ/g lipid) Daily intake
(pg-TEQ/kg b.w./day)
 Median Average
07–0.0002 0.00013 0.00014 0.0006
0–0.00016 0.000062 0.000071 0.0003
13–0.48 0.26 0.28 1.3
11–0.41 0.14 0.20 0.89
17–0.54 0.26 0.31 1.4
06–0.001 0.0001 0.0002 0.00097
0–0.00023 0.00009 0.0001 0.0005
08–0.56 0.22 0.25 1.1
91–0.39 0.22 0.20 0.92
14–0.62 0.39 0.36 1.6
ta are shown as means of duplicate samples from primiparous (n = 4) and
onatal delivery in Japan.
oncentration (pg-TEQ/g lipid) Daily intake
(pg-TEQ/kg b.w./day)
 Median Average
06–0.0004 0.000093 0.000172 0.0008
02–0.0003 0.00024 0.00023 0.0010
.21–0.37 0.28 0.29 1.3
47–0.27 0.18 0.17 0.75
.18–0.29 0.28 0.25 1.1
07–0.0002 0.0001 0.0001 0.0006
06–0.0002 0.0001 0.0001 0.0005
.14–0.66 0.34 0.37 1.7
41–0.24 0.11 0.13 0.56
0.1–0.39 0.26 0.25 1.1
ta are shown as means of duplicate samples from primiparous (n = 4) and
H. Kakutani et al. / Toxicology Reports 2 (2015) 685–691 689
Fig. 1. Contribution rates of PCDDs/DFs, PXDDs/DFs, Co-PCBs and Co-
PXB congeners to total TEQ and actual concentrations of dioxin analogs
in  breast milk from Japanese donors. Contribution indicated as ratios
(%)  of (A) total TEQ concentrations of four dioxin analogs (PCDDs/DFs,
PXDDs/DFs, Co-PCBs and Co-PXBs), (B) total actual concentration of
ﬁve Co-PXB congeners and (C) total TEQ concentrations of ﬁve Co-PXB
congeners. TEQ concentrations of Co-PXBs were calculated based on
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Fig. 2. Induction of cytochrome P450 1A activity in HepG2 cells incubated
with Co-PXBs. HepG2 cells were incubated with 10 nM Co-PXBs for various
lengths of time (A) and at various concentrations for 8 h (B), and then EROD
activity was  measured. Relative activity is expressed as fold induction
compared with vehicle. Data are shown as means ± SD (n = 5). Abbrevi-
ations: #126-Br, 4′-monobromo-3,3′ ,4,5-tetrachlorobiphenyl; #126-2Br,ssumption of similar toxicity between corresponding Co-PXB and Co-
CB  congeners. Data are shown as means (primiparous, n = 4; multiparous,
 = 6).
he other hand, #126-Br, #126-3Br and #169-Br accounted
or over 99% of the total TEQ concentration. Therefore, the
oxicity of Co-PXB congener type #126 required evaluation
s a human contaminant.
.2. Cytochrome P450 1A activity induced by Co-PXBs
etermined as activity of EROD in vitro
Because PCB #126 was the most toxic Co-PCB and had
ioxin-like activities, we focused on its congeners in which
romine was substituted with chlorine. We  assayed EROD
ctivity in HepG2 cells to determine whether Co-PXBs
nduced P450 1A activity. Fig. 2A shows that Co-PXBs time-
ependently increased intracellular EROD activity and that
t peaked at 6 h; thereafter, the peak activity was sustained3,4-dibromo-3′ ,4′ ,5′-trichlorobiphenyl; #126-3Br, 3′4′5′-tribromo-3,4-
dichlorobiphenyl; PBB: 3,3′ ,4,4′ ,5′-pentabromobiphenyl; PCB, 3,3′ ,4,4′ ,5-
pentachlorobiphenyl.
for 24 h (data not shown). The initial response times on
time-response curves were similar among Co-PXB con-
geners. The activity of EROD dose-dependently increased
at 8 h (Fig. 2B). However, the dose–response curves for
#126-3Br and PBB obviously differed from those of PCB,
#126-Br and #126-2Br. The EC50 values for EROD activ-
ity with TCDD, PCB, #126-Br, #126-2Br, #126-3Br and PBB
were 0.19, 163.1, 149.4, 128.9, 13.78 and 9.51 nM,  respec-
tively. We  calculated the REPs of Co-PXBs to determine the
relative toxicity of Co-PXBs based on their EC50 values. The
REPs for PCB, #126-Br, #126-2Br, #126-3Br and PBB were
0.0010, 0.0011, 0.0012, 0.0171 and 0.022, respectively. On
the other hand, 1 M #105-Br and #118-Br did not affect
EROD activities, and the cytotoxicity was shown at over
1 M (data not shown).
3.3. Changes in EROD activity in mice exposed to Co-PXBs
We  assayed EROD activity in vivo using liver micro-
somes collected from C57BL/6 mice administered with
Co-PXBs to conﬁrm differences in EROD activity elicited
by Co-PXBs in vitro. The activity of EROD induced by Co-
PXBs dose-dependently increased (Fig. 3A). Activity did
not signiﬁcantly differ among the congeners at 50 nmol/kg,
whereas at 5 and 10 nmol/kg, #126-3Br and PBB increased
EROD activity more signiﬁcantly than the other Co-PXB
congeners, providing a 5.2- and 4.9-fold relative increase
in the activity of PCB-treated mouse microsomes at
690 H. Kakutani et al. / Toxicology Re
Fig. 3. CYP1A activity is enhanced in mouse liver microsomes incu-
bated with Co-PXB. Mice were orally administered with Co-PXBs
at  5, 10 and 50 nmol/kg and then EROD activity was measured in
liver microsomes 2 days later (A). Mice were orally administered
with Co-PXBs at 10 nmol/kg and then EROD activity was measured
in liver microsomes at 1, 2 and 3 days later (B). Relative activity
is  expressed as fold induction compared with vehicle. Data are pre-
sented as means ± SE (n = 10). *P < 0.05 and **P < 0.01 compared with
same concentration or same length of incubation with PCB. Abbrevia-
tions: #126-Br, 4′-monobromo-3,3′ ,4,5-tetrachlorobiphenyl; #126-2Br,
3,4-dibromo-3′ ,4′ ,5′-trichlorobiphenyl; #126-3Br, 3′4′5′-tribromo-3,4-
dichlorobiphenyl; PBB, 3,3′ ,4,4′ ,5′-pentabromobiphenyl; PCB, 3,3′ ,4,4′ ,5-
pentachlorobiphenyl.
10 nmol/kg, respectively. Fig. 3B shows that PCB, #126-Br
and #126-2Br time-dependently decreased EROD activity
in mouse microsomes. On the other hand, #126-3Br and
PBB time-dependently increased the EROD activity, which
remained the same between Days 2 and 3. These results
indicated that introducing bromine into the chemical frame
of a polychlorinated biphenyl tends to increase the expres-
sion of CYP1A activity in vitro and in vivo.
4. Discussion
Brominated ﬂame retardants currently occupy the
largest market share among such compounds because they
are inexpensive and very efﬁcient. However, although reg-
ulations and restrictions have recently increased regarding
the production and use of BFRs due to safety concerns
[18,19], an estimated 48,000 tons of BFRs were used in
Japan during 2009 [20]. Schäfer and Ballschmiter reported
that PBDDs/DFs and PXDDs/DFs are generated as unde-
sirable by-products of plastics containing BFRs that are
burned in MSW  incinerators [8], and 1,243 incinerators
burn about 34.5 million tons/year of MSW  in Japan [21].
Similar to PBDDs/DFs and PXDDs/DFs formed in MSW
incinerators, Co-PXBs can be also formed by de novo syn-
thesis from precursor BFRs. There were only low levels of
Co-PXB contamination in breast milk of donors in Spainports 2 (2015) 685–691
with a little amount of waste incinerated and BFRs com-
pared in Japan [10]. Therefore, the contamination of breast
milk with Co-PXBs in Japan might reﬂect BFR combustion in
MSW  incinerators, and it may  be arose from regional asso-
ciation. A higher ratio of PXDDs/DFs is easier to generate
with a mixture of bromine and chlorine than of PBDDs/DFs
using all available bromine in an incinerator [1,2]. We esti-
mated that the same is true for Co-PXBs compared with
Co-PBBs during incineration under these respective con-
ditions, and therefore focused on Co-PXBs. The level of
pollution caused by these Co-PXBs as well as their tox-
icity in the environment and in humans is important to
understand.
The present study was  based on a previous investigation
that found high toxicity levels and high concentrations of
Co-PCB #126 in biological specimens such as breast milk
[22–24]. We evaluated ﬁve Co-PXB congeners and also
found high levels of Co-PXB contamination in breast milk
from Japanese donors. Because Co-PXBs account for 10% of
the total TEQ concentration and we  evaluated only ﬁve con-
geners, their contribution cannot be ignored. Although the
levels of Co-PCB contamination did not signiﬁcantly differ
between primiparous and multiparous donors, more Co-
PCB was found in breast milk at 5, than at 30 days after
birth, whereas this was  not consistently true of Co-PXBs.
These results suggested that the metabolism or excretion
of Co-PXBs and Co-PCBs differs. Notably, levels of Co-PXBs
are relatively high in infants due to intake through breast
milk. However, only a few studies have investigated Co-PXB
contamination and toxicity [10–12].
The EROD activity of CYP1A is widely used to determine
the induction of CYPs by dioxin-like compounds [13]. We
clariﬁed that the amount of EROD activity induced by Co-
PXBs and Co-PCBs was  similar, although most likely via
different pathways. Previous ﬁndings indicate that PCB is
metabolized to 4′-hydroxy-3,3′,4,5,5′-pentaclorobiphenyl
(OH-PCB) via 4′,5′-epoxide formation and a subsequent
NIH-shift of the 4′-chlorine to the 5′-position [25]. Halogen
atoms have a negative inductive effect and since this effect
of bromine (3,4,5-tribromine) is lower than that of chlorine
(3,4,5-trichlorine), #126-3Br was  less reactive than PCB. If
Co-PXBs were also metabolized via an NIH-shift, #126-3Br
would be more difﬁcult to metabolize than PCB. In addi-
tion, Dannan et al. reported that the bromination of both
para positions seems to render PBB resistant to microsomal
metabolism [26]. Based on these and the present ﬁndings,
we assumed that the substitution of bromine to the para
area (3,4,5-positions) of chlorinated biphenyl is necessary
to resist microsomal metabolism. The endocrine system is
targeted by OH-PCBs [27,28] that can be more toxic than
their precursor PCBs [29,30]. Consequently, further studies
are required to clarify Co-PXB metabolism and the dis-
ruptive effects of Co-PXBs and their metabolites on the
endocrine system.
In conclusion, we  showed that only ﬁve Co-PXB con-
geners signiﬁcantly and similarly contributed to the
amount of toxins in breast milk collected from primiparous
and multiparous donors in Japan. We  also showed that
the ability of Co-PCBs and Co-PXBs, especially #126-3Br
to induce CYP1A differ. If Co-PXBs are more toxic than Co-
PCBs, our ﬁndings suggest that the TEQ levels of Co-PXBs
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